Compare HOV & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOV | STTK |
|---|---|---|
| Founded | 1959 | 2016 |
| Country | United States | United States |
| Employees | 1891 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.5M | 538.3M |
| IPO Year | N/A | 2020 |
| Metric | HOV | STTK |
|---|---|---|
| Price | $109.07 | $6.12 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $97.00 | $10.00 |
| AVG Volume (30 Days) | 101.4K | ★ 522.7K |
| Earning Date | 05-19-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.96 | N/A |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $85.69 | $0.71 |
| 52 Week High | $162.06 | $8.33 |
| Indicator | HOV | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 42.87 |
| Support Level | $99.06 | $5.85 |
| Resistance Level | $113.60 | $6.81 |
| Average True Range (ATR) | 5.98 | 0.51 |
| MACD | 0.37 | -0.10 |
| Stochastic Oscillator | 59.51 | 25.16 |
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.